Sign inJoin waitlistJoin the waitlist

Jan Drappatz

Associate Director, Adult Neuro-Oncology Program · UPMC Medical Education

Credentials: · · · ·

History

Clinical Affairs - Hematology/Oncology · UPMC Medical Education
Present
Adult Neuro-Oncology Program · UPMC Medical Education
Present
UPMC Medical Education
Present

Dana-Farber Cancer Institute
2004–2005
Neurology
Massachusetts General Hospital
2001–2004
Preliminary Internal Medicine
Boston University Medical Center
1999–2000
California University of Science and Medicine - School of Medicine
1995–1999

Research

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Cancer Cell · 2007 · 1,410 citations
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
The Lancet Oncology · 2017 · 932 citations
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
Neurology · 2008 · 649 citations

PW
Patrick Wen
73 papers
Andrew Norden
36 papers · 19 as a fellow
Santosh Kesari
32 papers · 8 as a fellow
FL
Frank Lieberman
25 papers
Tracy Batchelor
23 papers
Eudocia Lee
22 papers
David Schiff
21 papers
Timothy Cloughesy
14 papers
Keith Ligon
13 papers
MM
Megan Mantica
13 papers · 1 as a fellow
Michael Prados
13 papers
David Reardon
12 papers

Clinical trials

A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Principal investigator · Active not recruiting · Phase 1, Phase 2
Hemerion Therapeutics
2024–2026
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Principal investigator · Active not recruiting · Phase 1
AstraZeneca
2018–2026
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma
Principal investigator · Unknown · Phase 1, Phase 2
TransMolecular
2008–2010
IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Site PI · Recruiting · Phase 3
Ono Pharmaceutical Co., Ltd.
2026–2029